IBDEI0YR ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17267,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17267,1,1,0)
 ;;=1^202.10
 ;;^UTILITY(U,$J,358.3,17267,1,8,0)
 ;;=8^Mycosis Fungoides
 ;;^UTILITY(U,$J,358.3,17267,2)
 ;;=^80360
 ;;^UTILITY(U,$J,358.3,17268,0)
 ;;=273.3^^111^1078^21
 ;;^UTILITY(U,$J,358.3,17268,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17268,1,1,0)
 ;;=1^273.3
 ;;^UTILITY(U,$J,358.3,17268,1,8,0)
 ;;=8^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,17268,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,17269,0)
 ;;=203.00^^111^1078^28
 ;;^UTILITY(U,$J,358.3,17269,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17269,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,17269,1,8,0)
 ;;=8^Multiple Myeloma,W/O Remission
 ;;^UTILITY(U,$J,358.3,17269,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,17270,0)
 ;;=203.01^^111^1078^27
 ;;^UTILITY(U,$J,358.3,17270,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17270,1,1,0)
 ;;=1^203.01
 ;;^UTILITY(U,$J,358.3,17270,1,8,0)
 ;;=8^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,17270,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,17271,0)
 ;;=202.40^^111^1078^8
 ;;^UTILITY(U,$J,358.3,17271,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17271,1,1,0)
 ;;=1^202.40
 ;;^UTILITY(U,$J,358.3,17271,1,8,0)
 ;;=8^Hairy-Cell Leukemia
 ;;^UTILITY(U,$J,358.3,17271,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,17272,0)
 ;;=200.10^^111^1078^18
 ;;^UTILITY(U,$J,358.3,17272,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17272,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,17272,1,8,0)
 ;;=8^Lymphoma,Int/High (Diffuse)
 ;;^UTILITY(U,$J,358.3,17272,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,17273,0)
 ;;=273.1^^111^1078^25
 ;;^UTILITY(U,$J,358.3,17273,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17273,1,1,0)
 ;;=1^273.1
 ;;^UTILITY(U,$J,358.3,17273,1,8,0)
 ;;=8^Monoclon Paraproteinemia
 ;;^UTILITY(U,$J,358.3,17273,2)
 ;;=^78888
 ;;^UTILITY(U,$J,358.3,17274,0)
 ;;=238.79^^111^1078^20
 ;;^UTILITY(U,$J,358.3,17274,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17274,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,17274,1,8,0)
 ;;=8^Lymphoproliferat Dis
 ;;^UTILITY(U,$J,358.3,17274,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,17275,0)
 ;;=202.90^^111^1078^17
 ;;^UTILITY(U,$J,358.3,17275,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17275,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,17275,1,8,0)
 ;;=8^Lymphoma,Diffuse,Unspec Site
 ;;^UTILITY(U,$J,358.3,17275,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,17276,0)
 ;;=200.30^^111^1078^23
 ;;^UTILITY(U,$J,358.3,17276,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17276,1,1,0)
 ;;=1^200.30
 ;;^UTILITY(U,$J,358.3,17276,1,8,0)
 ;;=8^Marginal Zone Lymphoma
 ;;^UTILITY(U,$J,358.3,17276,2)
 ;;=^335296
 ;;^UTILITY(U,$J,358.3,17277,0)
 ;;=200.40^^111^1078^22
 ;;^UTILITY(U,$J,358.3,17277,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17277,1,1,0)
 ;;=1^200.40
 ;;^UTILITY(U,$J,358.3,17277,1,8,0)
 ;;=8^Mantle Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,17277,2)
 ;;=^335297
 ;;^UTILITY(U,$J,358.3,17278,0)
 ;;=200.50^^111^1078^32
 ;;^UTILITY(U,$J,358.3,17278,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17278,1,1,0)
 ;;=1^200.50
 ;;^UTILITY(U,$J,358.3,17278,1,8,0)
 ;;=8^Prim CNS Lymphoma
 ;;^UTILITY(U,$J,358.3,17278,2)
 ;;=^335298
 ;;^UTILITY(U,$J,358.3,17279,0)
 ;;=200.60^^111^1078^4
 ;;^UTILITY(U,$J,358.3,17279,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17279,1,1,0)
 ;;=1^200.60
 ;;^UTILITY(U,$J,358.3,17279,1,8,0)
 ;;=8^Anaplastic Large Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,17279,2)
 ;;=^335299
 ;;^UTILITY(U,$J,358.3,17280,0)
 ;;=200.70^^111^1078^13
 ;;^UTILITY(U,$J,358.3,17280,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17280,1,1,0)
 ;;=1^200.70
 ;;^UTILITY(U,$J,358.3,17280,1,8,0)
 ;;=8^Large Cell Lymphoma
